Business Wire

Market Vectors Announces Investment Agreement with Australian Index Investments (Aii), Plans Expansion of ETF Distribution in Australia

19.6.2012 16:05:08 CEST | Business Wire | Press release

Share
NY-VAN-ECK-GLOBAL

Market Vectors ETFs today announced that its investment adviser, Van Eck Associates Corporation, had entered into an Investment Agreement with Australian Index Investments (Aii) on June 7, 2012. The resulting company is a majority-owned subsidiary of Van Eck Associates Corporation and will be renamed Market Vectors Australia Pty Ltd .

Market Vectors Australia will market and distribute exchange-traded funds (ETFs), including six existing Aii ETFs, to the Australian marketplace. The company currently oversees approximately AUD $30 million in investor assets. The current Aii staff will be retained and led by CEO Annmaree Varelas.

“We are pleased to have entered into this agreement,” said Ms. Varelas. “We are in a unique position to grow our ETF business by partnering with the very successful U.S-based Market Vectors ETFs. We hope to increase and improve investment choices available to Australian investors by building a full product line over time.” Ms. Varelas has served as CEO at Aii for two years. She also has extensive experience as Manager of Funds, Warrants & Structured Products at the Australian Securities Exchange and was instrumental in establishing the AQUA Market for ETFs in Australia.

Australia’s $1.8 trillion managed fund market is the fourth-largest in the world and is largely dominated by the superannuation and rollover segments (which gained $14 billion in net inflows during 2011)1 . The Australian ETF market remains in its infancy with indications of growth to come. There are currently approximately 70 funds and $5 billion in assets under management2 .

“The launch of Market Vectors Australia is an important milestone,” said Lars Hamich, Managing Director of International Business Development at Market Vectors. “We look forward to expanding our global presence in a marketplace ripe with growth opportunity.” Market Vectors is a key player in the well-established U.S. ETF market. It currently totals $25.1 billion in assets under management, ranking as fifth largest ETP provider in the United States and eighth largest worldwide as of March 31, 2012. Headquartered in New York City, the firm has a presence in other cities worldwide, including Shanghai (China), Frankfurt (Germany), Madrid (Spain) and Pfaeffikon (Switzerland).

About Market Vectors ETFs

The Market Vectors family of exchange-traded funds has been offered in the U.S. since 2006 and currently comprises 49 ETFs spanning international, hard assets, industry-specific, income-oriented, and broad-based asset classes. Market Vectors ETFs are sponsored by Van Eck Global . Founded in 1955, Van Eck Global was among the first U.S. money managers helping investors achieve greater diversification through global investing. Today, the firm continues this tradition by offering innovative, actively managed investment choices in hard assets, emerging markets, precious metals including gold, and other alternative asset classes. Including its ETF business, the firm manages an aggregate $34.8 billion in investor assets as of March 31, 2012.

About Australian Index Investments (Aii)

Australian Index Investments is a provider of Australian sector-specific exchange-traded funds (ETFs) listed on the Australian Securities Exchange (ASX). Australian Index Investments’ existing offerings include six passively managed ETFs that track the performance of S&P/ASX indices:

Existing Aii ETF ASX Code
Aii S&P/ASX 200 Financials FIN
Aii S&P/ASX 200 Financials x-A-REIT FIX
Aii S&P/ASX 200 Resources RSR
Aii S&P/ASX 200 Industrials IDD
Aii S&P/ASX 200 Energy ENY
Aii S&P/ASX 300 Metals and Mining MAM

Additional Information

Sydney Capital Partners and Right Wall Capital served as advisors to Aii and Van Eck Associates Corporation, respectively.

Sources: 1 Strategic Insights, May 2012; 2 ETF Trends, June 6, 2012.

The Aii Sector ETFs are issued by Valuestream Investment Management (ACN 099 107 034) (AFSL No 246621) (‘VIML’) under a Product Disclosure Statement (‘PDS’) for the Aii Sector ETFs. Copies of the PDS are available on the Aii website www.australianindexinvestments.com.au or by contacting Aii on 1800 256 267. The PDS contains information on how to trade the Aii Sector ETFs. Please read the entire PDS before making any investment decision.

This information has been prepared for promotional purposes only and is not intended to amount to advice or a recommendation to invest in the Aii Sector ETFs and does not constitute an offer or an invitation to purchase or subscribe for the Aii Sector ETFs. It does not take into account your investment objectives, financial situation or particular needs. You should seek professional advice on these matters before making an investment decision.

“S&P” is a trademark of Standard & Poor’s Financial Services LLC and “ASX” is a trademark of ASX Operations Pty Ltd. These trademarks have been licensed for use by Australian Index Investments Pty Ltd. The Aii S&P/ASX 200 Financials ETF, the Aii S&P/ASX 200 Financials x-A-REIT ETF, the Aii S&P/ASX 200 Industrials ETF, the Aii S&P/ASX 200 Resources ETF, the Aii S&P/ASX 200 Energy ETF and the Aii S&P/ASX 300 Metals and Mining ETF are not sponsored, endorsed, sold or promoted by Standard & Poor’s or ASX Operations Pty Ltd. Standard & Poor’s and ASX Operations Pty Ltd make no recommendation as to the advisability of investing in the Aii S&P/ASX 200 Financials ETF, the Aii S&P/ASX 200 Financials x-A-REIT ETF, the Aii S&P/ASX 200 Industrials ETF, the Aii S&P/ASX 200 Resources ETF, the Aii S&P/ASX 200 Energy ETF and the Aii S&P/ASX 300 Metals and Mining ETF. Various sector ETFs are referred to in this press release. Such references should not be construed as an express or implied endorsement of the sector ETFs by Aii or VIML. Returns on the Aii Sector ETFs are not guaranteed.

The “Net Asset Value” (NAV) of a Market Vectors exchange-traded fund (ETF) is determined at the close of each business day, and represents the dollar value of one share of the fund; it is calculated by taking the total assets of the fund, subtracting total liabilities, and dividing by the total number of shares outstanding. The NAV is not necessarily the same as the ETF’s intraday trading value. Market Vectors ETF investors should not expect to buy or sell shares at NAV.

Fund shares are not individually redeemable and will be issued and redeemed at their NAV only through certain authorized broker-dealers in large, specified blocks of shares called “creation units” and otherwise can be bought and sold only through exchange trading. Creation units are issued and redeemed principally in kind. Shares may trade at a premium or discount to their NAV in the secondary market.

Investing involves substantial risk and high volatility, including possible loss of principal. An investor should consider the investment objective, risks, charges and expenses of the Fund carefully before investing. To obtain a prospectus and summary prospectus , which contains this and other information, call 888.MKT.VCTR or visit marketvectorsetfs.com. Please read the prospectus and summary prospectus carefully before investing.

Van Eck Securities Corporation, Distributor, 335 Madison Avenue, New York, NY 10017

Contact:

MacMillan Communications
212-473-4442
Mike MacMillan
mike@macmillancom.com
Market Vectors Australia
Annmaree Varelas
annmaree@aiifunds.com.au

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye